The immediate dilutive impact of this offering will pressure NTHI shares. Monitor for the stock to trade below the $4.20 offering price as the market absorbs the new supply. The 30-day company standstill and 90-day insider lock-up provide a temporary floor, but the company's ongoing cash burn and history of repeated dilutive financings suggest further weakness. Consider short-term bearish positioning.
Price Chart
Executive Summary
NeOnc Technologies is raising approximately $13.9M in net proceeds through a registered direct offering of 2,610,715 shares of common stock, 960,715 pre-funded warrants, and 3,571,430 warrants at a combined price of $4.20 per share and warrant. The offering, priced at a slight premium to the $4.07 closing price on September 8, 2026, will dilute existing shareholders by roughly 14% and is intended for general corporate purposes and to redeem Series A Convertible Preferred Stock. This is the latest in a series of dilutive financings for a pre-revenue clinical-stage biotech with an accumulated deficit of $135.8M, reinforcing a bearish outlook on the stock.
Key Facts
- Offering of 2,610,715 shares of common stock, 960,715 pre-funded warrants, and 3,571,430 warrants at $4.20 per unit.
- Net proceeds to the company are approximately $13.9 million after fees and expenses.
- Pro forma shares outstanding will increase to 29,766,095 from 26,194,665, representing ~14% dilution.
- Net tangible book value per share will worsen to $(0.17) from $(0.73), with new investors facing $4.37 per share dilution.
- Company had $0 revenue from product sales and an accumulated deficit of $135.8M as of June 30, 2026.
- Proceeds intended for general corporate purposes, working capital, and redemption of Series A Convertible Preferred Stock.
- CEO and Chief Medical Officer are subject to a 90-day lock-up; company has a 30-day standstill on further equity issuance.
Financial Impact
~$13.9M net proceeds raised, with potential additional ~$15M from warrant exercise. Dilution of ~14% to existing shareholders.
Risk Factors
- Further dilution if warrants are exercised for cash.
- Company may need additional dilutive financing before reaching clinical milestones.
- No approved products or revenue; reliance on successful clinical trials for NEO100 and NEO212.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001829126-26-009976 |
| Document: 0001829126-26-009976-index-headers.html | 0001829126-26-009976 |
| Document: 0001829126-26-009976-index.html | 0001829126-26-009976 |
| Document: 0001829126-26-009976.txt | 0001829126-26-009976 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $3.27 | awaiting T+60 | — | $3.27 (−0.00%) |
Oct 15, 2026 11d ago | 8-K | $2.70 | awaiting T+60 | — | $3.27 (+21.11%) |
Sep 18, 2026 5w ago | Insider Cluster | $3.33 | awaiting T+60 | — | $3.27 (−1.80%) |
Sep 17, 2026 5w ago | 8-K | $3.41 | awaiting T+60 | — | $3.27 (−4.11%) |
Sep 15, 2026 5w ago | Insider Cluster | $2.99 | awaiting T+60 | — | $3.27 (+9.36%) |
Sep 10, 2026 6w ago | 8-K | $3.66 | awaiting T+60 | — | $3.27 (+10.66%) |
Sep 10, 2026 6w ago | 424B5 | $3.66 | awaiting T+60 | — | $3.27 (+10.66%) |
Aug 20, 2026 9w ago | Insider Cluster | $4.68 | awaiting T+60 | — | $3.27 (−30.05%) |
Aug 18, 2026 9w ago | Insider Cluster | $5.53 | awaiting T+60 | — | $3.27 (−40.87%) |
Aug 12, 2026 10w ago | 8-K | $3.46 | awaiting T+60 | — | $3.27 (−5.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers